Effective July 14, Spooner takes responsibility for overseeing the finance function for Medtronic Diabetes/MiniMed. His role includes supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as the unit prepares to become independent.
The medtech giant announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. The move sought to create “a more focused Medtronic” with a more simplified portfolio in high-margin growth markets. At the same time, it creates an independent, scaled leader in diabetes, called MiniMed.
“I’m excited for the opportunity to help shape the future of a company with such a meaningful mission, and I look forward to working with [future MiniMed CEO Que Dallara] and the leadership team to build a strong, agile finance organization that supports innovation, drives sustainable growth, and creates long-term value for all stakeholders,” said Spooner.
More about future Medtronic Diabetes/MiniMed CFO Chad Spooner
Spooner offers more than 25 years of experience in financial leadership across the healthcare, consumer and industrial sectors. Most recently, he served as CFO of BIC, a publicly traded global consumer goods leader.
He started his career at General Electric, holding positions of increasing responsibility in corporate audit and financial planning. After GE, Spooner took over as CFO at Raffaela Apparel Group and Slingshot Health, He also held senior operational finance roles at Tenex Capital Management, a private equity firm he co-founded.
“We’re excited to welcome Chad to the executive team at such a pivotal time for our business,” said Dallara, EVP and president of Medtronic Diabetes and CEO designate of MiniMed. “Chad’s deep financial expertise, impressive track record, and proven leadership in driving transformation and growth will be instrumental as we prepare for our next chapter as an independent company. His appointment underscores our commitment to building a strong foundation for long-term success so we can continue to enhance the lives of individuals with diabetes we’re privileged to serve.”
